Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

@article{Kathmann2006CannabidiolIA,
  title={Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors},
  author={Markus Kathmann and Karsten Flau and Agnes Redmer and Christian Tr{\"a}nkle and E Schlicker},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2006},
  volume={372},
  pages={354-361}
}
The mechanism of action of cannabidiol, one of the major constituents of cannabis, is not well understood but a noncompetitive interaction with mu opioid receptors has been suggested on the basis of saturation binding experiments. The aim of the present study was to examine whether cannabidiol is an allosteric modulator at this receptor, using kinetic binding studies, which are particularly sensitive for the measurement of allosteric interactions at G protein-coupled receptors. In addition, we… Expand
Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity
TLDR
The inhibitory actions indicate an antagonistic behavior towards DOR which was established by the followings: rimonabant inhibited DOR antagonist binding more effectively than agonist binding, the inverse agonistic, agonistic effect of the compound can be excluded, and the allosteric mechanism can be foreclosed. Expand
The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes
TLDR
It is concluded that neither anandamide nor WIN 55,212-2 directly activate or modulate mu opioid receptor function in oocytes and that interactions of cannabinoids with mu opioid receptors are likely to be indirect. Expand
Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors
TLDR
It is confirmed that CBD does not bind with high affinity to the orthosteric site of the human CB2R where the synthetic cannabinoid, [3H]-WIN 55,212-2, binds, and CBD was, however, able to produce minor but consistent reduction in the homogeneous binding assays in living cells using the fluorophore-conjugatedCB2R-selective compound, CM-157. Expand
Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors
TLDR
This study clarified whether the decreased MOR activation caused by NE could be reversed by rimonabant in CB(1) receptor deficient mice and suggested that other, yet unidentified mechanisms are additionally involved in the observed effects. Expand
Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner
TLDR
Rimonabant reduced KOR ligand binding, receptor mediated G-protein activity and protein expression level, which overall leads to altered anxiety-like behavior. Expand
Cannabidiol and 5-HT1A Receptors
Abstract Cannabidiol (CBD), the major nonpsychotomimetic compound present in the Cannabis sativa plant, is a promising drug to treat several neuropsychiatric and nonneuropsychiatric disorders.Expand
CB1 receptors modulate the intake of a sweetened-fat diet in response to mu-opioid receptor stimulation of the nucleus accumbens
TLDR
Data suggest an important modulatory role for cannabinoid receptors in the expression of feeding behaviors in response to mu-opioid receptor activation of the nucleus accumbens shell, and this role may be important in the response to opioid and cannabinoid ligands. Expand
Effects of cannabidiol on the function of α7-nicotinic acetylcholine receptors.
TLDR
CBD inhibits the function of the α7-nACh receptor, a cloned α7 subunit of the human nicotinic acetylcholine (α7 nACh) receptor expressed in Xenopus oocytes, and phytocannabinoids such as cannabinol and Δ(9)-tetrahydrocannabinol did not affect ACh-induced currents. Expand
Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain
TLDR
An important role for CB1R-DOR heteromers in altered cortical function of DOR during neuropathic pain is demonstrated and the possibility that a novel heteromer-directed therapeutic strategy for enhancing DOR activity, could potentially be employed to reduce anxiety associated with chronic pain is suggested. Expand
Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
TLDR
From a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2, the bivalent compound has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Modulation of rat brain opioid receptors by cannabinoids.
TLDR
Delta 9-THC inhibited the binding of [3H]etorphine (potent opioid agonist) to solubilized, partially purified opioid receptors with a Ki value similar to that observed for the membrane-bound receptors, indicating that the allosteric modulation of the opioid receptor by delta 9- THC is the result of a direct interaction with the receptor protein or with a specific protein-lipid complex. Expand
Pharmacology of cannabinoid receptor ligands.
  • R. Pertwee
  • Chemistry, Medicine
  • Current medicinal chemistry
  • 1999
TLDR
This review summarizes current knowledge about the in vitro pharmacological properties of important CB1 and CB2 receptor ligands and pays particular attention to the binding properties of these ligands, to the efficacies of cannabinoid receptor agonists, as determined using cyclic AMP or [35S]GTPgammaS binding assays, and to selected examples of how these pharmacological Properties can be influenced by chemical structure. Expand
The effects of cannabinoids on the brain
  • A. Ameri
  • Medicine, Chemistry
  • Progress in Neurobiology
  • 1999
TLDR
Cannabinoids share a final common neuronal action with other major drugs of abuse such as morphine, ethanol and nicotine in producing facilitation of the mesolimbic dopamine system. Expand
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
TLDR
This review focuses on the CB1-selective antagonists, SR141716A, AM251, AM281 and LY320135, and discusses possible mechanisms by which these ligands produce their inverse effects. Expand
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
TLDR
It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking. Expand
Modulation of transmitter release via presynaptic cannabinoid receptors.
TLDR
The effects of modulation of transmitter release by cannabinoids in both the CNS and the PNS of various species, including humans, will be discussed. Expand
[3H]naltrindole: a potent and selective ligand for labeling delta-opioid receptors.
TLDR
It is demonstrated that [3H]NTI is a potent and selective radioligand for delta-opioid receptors in rat brain preparations and was not significantly inhibited by mu- or kappa-OPioid ligands or by nonopIOid compounds. Expand
Modulation of brain α2-adrenoceptor and μ-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats
SummaryThe densities of brain α2-adrenoceptors and μ-opioid receptors, quantitated by means of the binding of the agonists [3H]clonidine and [3H]dihydromorphine, respectively, were studied during theExpand
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.
TLDR
It is concluded that cannabidiol antagonizes R-(+)-WIN55212 and CP55940 by acting at prejunctional sites that are unlikely to be cannabinoid CB(1) or CB(2) receptors. Expand
Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.
TLDR
The present results indicate that compounds that can act allosterically may compete with acetylcholine for primary receptor sites but that allosteric effects of these drugs on muscarine receptors are not likely to be important clinically. Expand
...
1
2
3
4
5
...